Title:	Advances in nanocarriers as drug delivery systems in Chagas disease
Authors:	Quijia Quezada, Christian Azevedo, Clênia dos Santos Charneau, Sébastien Santana, Jaime Martins Chorilli, Marlus Carneiro, Marcella Bretas Bastos, Izabela Marques Dourado
Assunto::	Nanopartículas Nanobiossensores Diagóstico Chagas, Doença de - tratamento Vacinas
Issue Date:	9-Aug-2019
Publisher:	Dove Press
Citation:	QUIJIA QUEZADA, Christian et al. Advances in nanocarriers as drug delivery systems in Chagas disease. International Journal of Nanomedicine, v. 14, p. 6407–6424, 2019. DOI: https://doi.org/10.2147/IJN.S206109. Disponível em: https://www.dovepress.com/advances-in-nanocarriers-as-drug-delivery-systems-in-chagas-disease-peer-reviewed-article-IJN. Acesso em: 09 abr. 2020.
Abstract:	Chagas disease is one of the most important public health problems in Latin America due to its high mortality and morbidity levels. There is no effective treatment for this disease since drugs are usually toxic with low bioavailability. Serious efforts to achieve disease control and eventual eradication have been unsuccessful to date, emphasizing the need for rapid diagnosis, drug development, and a reliable vaccine. Novel systems for drug and vaccine administration based on nanocarriers represent a promising avenue for Chagas disease treatment. Nanoparticulate systems can reduce toxicity, and increase the efficacy and bioavailability of active compounds by prolonging release, and therefore improve the therapeutic index. Moreover, nanoparticles are able to interact with the host’s immune system, modulating the immune response to favour the elimination of pathogenic microorganisms. In addition, new advances in diagnostic assays, such as nanobiosensors, are beneficial in that they enable precise identification of the pathogen. In this review, we provide an overview of the strategies and nanocarrier-based delivery systems for antichagasic agents, such as liposomes, micelles, nanoemulsions, polymeric and non-polymeric nanoparticles. We address recent progress, with a particular focus on the advances of nanovaccines and nanodiagnostics, exploring new perspectives on Chagas disease treatment.
Licença::	© 2019 Quijia Quezada et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)
Appears in Collections:	Artigos publicados em periódicos e afins

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.